Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Non Inferiority Study of a Reduced Dose of Activated Charcoal on Rivaroxaban Pharmacokinetics

Next Previous
X
Search
Trial Profile

Non Inferiority Study of a Reduced Dose of Activated Charcoal on Rivaroxaban Pharmacokinetics

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivaroxaban (Primary) ; Charcoal
  • Indications Acute coronary syndromes; Arterial thrombosis; Cardiovascular disorders; Coronary thrombosis; Deep vein thrombosis; Embolism; Heart failure; Peripheral arterial disorders; Pulmonary embolism; Stroke; Thromboembolism; Thrombosis; Venous thromboembolism; Venous thrombosis
  • Focus Pharmacokinetics
  • Acronyms RICHAR2

    • Most Recent Events

    • 02 Dec 2022 Status changed from recruiting to completed.
    • 14 Feb 2022 Planned End Date changed from 1 Apr 2022 to 1 Jan 2023.
    • 14 Feb 2022 Planned primary completion date changed from 1 Apr 2022 to 1 Dec 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top